Puridify wins prestigious bioprocess industry award

Industry recognition for single-use mAb purification technology that significantly increases productivity

London, UK – 21 October 2016 – Puridify Limited ("Puridify"), a developer of novel bioprocessing purification technologies for industrial biomolecule manufacture, has won a 2016 BioProcess International Award for best collaboration with GlaxoSmithKline to advance industrial evaluation of Puridify's FibroSelect. These prestigious industry awards celebrate the outstanding people, organisations, and technologies that define excellence and enable more effective, less expensive biotherapeutic development and manufacturing. The winners were announced at a special ceremony during the 2016 BPI International Conference and Exhibition in Boston, Massachusetts, US earlier this month.

The **Best Collaboration** award recognises "partnerships that have proven to result in significant benefits toward accelerating drug development". Puridifiy won the award for their highly complementary collaboration with GSK for the past 12 months to develop and evaluate Puridify's nanofibre single-use purification technology, FibroSelect, from microlitre to 50L pilot scale and knowledge sharing in the process. The initial collaboration has resulted in a 50-fold increase in purification productivity compared to traditional packed columns and has been extended for a further 18 months to drive towards full industrial scale purifying feed from >500L bioreactors.

In addition to winning best collaboration, Puridify were also named a finalist for **Best Downstream Technology Application** for their FibroSelect platform purification technology.

Oliver Hardick, CEO of Puridify commented: "Winning Best Collaboration not only signals the interest that FibroSelect is generating in the industry, but is also a testament to the dedication and expertise of our R&D team. GSK's willingness to engage in such a valuable collaboration has enabled us to demonstrate the huge productivity gains that our technology platform can offer. We're now focused on moving towards commercial manufacture of FibroSelect and scaling up our evaluation efforts with a range of industrial support."

- END -

Notes to Editors

BioProcess International Awards
The BioProcess International Awards celebrate the outstanding achievements, collaborations, business strategies, social corporate responsibility and technology applications that will allow the industry to deliver better, more effective treatments to a global patient base. Judged by a distinguished panel of independent biopharmaceutical experts, and supported by bioprocess specialist publication *BioProcess International*, the awards ceremony took place during the BioProcess International Conference on the evening of Wednesday, 5 October 2016.

About Puridify Ltd
Puridify Limited is a UK-based bioprocessing company with a platform purification technology, FibroSelect, which enables new processing strategies aimed at significantly reducing the cost and time associated with manufacture. The company is funded by leading venture capital investors Imperial Innovations and SR One who recognised the significant value that Fibroselect can release to a large and growing marketplace that is seeking efficiency but which has seen little in the way of innovation. Puridify's head office and research & development facilities are based at the Stevenage Bioscience Catalyst. The company works closely with industry experts and leading industrial collaborators from around the world, to drive the rapid development of its platform technologies.

Puridify has secured a number of prestigious awards, including the SR-One funded OneStart Competition and Innovate UK Proof of Concept Bid to Smart Award in 2013; Innovate UK's Feasibility Studies and Collaborative R&D Awards in 2014; and this year received an Innovate UK Industrial Biotechnology Catalyst Project award, co-funded by the Engineering and Physical Sciences Research Council (EPSRC) and the Biotechnology and Biological Sciences Research Council (BBSRC).

For more information, visit www.puridify.com

Biotherapeutic Industry Context
Global demand for cheaper biotherapeutics, such as antibodies and vaccines, and the growth of biosimilars, which represent many of the new tools in the fight against diseases such as cancer, inflammation and neurodegenerative conditions, is driving the need for increased efficiency in biomolecule manufacturing. A significant proportion of current costs arise from the purification technologies now used to ensure the safety and efficacy of these treatments. Recent rapid evolution of the global biopharmaceutical market has drawn focus to the limitations of current purification operations, demanding a step-change improvement in processes. The rapid development of "Next Generation" biotherapeutics of increased complexity and size in addition to a focus on process efficiency, flexibility and convenience during manufacturing is driving the need for innovative but robust technologies that enable new platform processing strategies.

About FibroSelect
Puridify has leveraged proprietary technology with industrial expertise to develop industry-ready products that will bring significant simplification and performance benefits to downstream processing of biotherapeutics. The unique high capacity (Dynamic Binding Capacities comparable to packed beds) combined with high flowrate properties (3 minute chromatography runs) of FibroSelect enables the replacement of columns that are >50x larger. This is achieved by using a 'multi-cycle, single batch' mode of operation that greatly improves productivity allowing the operation to be shrunk to the point that single-use operation is economically viable. These highly cost effective, ready-to-use units will reduce validation burden, improve process robustness and increase facility flexibility.

FibroSelect simplifies chromatography so that it can behave in a way akin to adsorptive depth filters whilst maintaining compatibility with existing facility infrastructure. Making use of well understood materials, such as cellulose, also allows a broad scope of current ligands, such as Protein A, to be used with FibroSelect as a solution in costly product-capture applications. The performance and operating characteristics offer highly desirable rapid process development opportunities valued by the biopharmaceutical industry.

For more information, please contact:

Dr Oliver Hardick, Chief Executive Officer
Puridify Ltd
E: info@puridify.com

Media enquiries to Instinctif Partners
Dr Lynne Trowbridge, Tim Watson, Dr Priya Kalia, Dr Samantha Cheung, Alex Bannister
T: +44 20 7866 2825
E: puridify@instinctif.com